{
  "nodes": [
    {
      "id": "node_001",
      "content": "BRAF V600E mutation",
      "parent_ids": [],
      "children_ids": [
        "node_002",
        "node_013"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "nn"
      ]
    },
    {
      "id": "node_002",
      "content": "BRAF V600E mutation discovered prior to first-line systemic therapy",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_003",
        "node_004",
        "node_005"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_003",
      "content": "Preferred\nDabrafenib + trametinib\nor\nEncorafenib + binimetinib",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_006"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "ss"
      ]
    },
    {
      "id": "node_004",
      "content": "Useful in Certain Circumstances\nDabrafenib or Vemurafenib",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_007"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "ss",
        "qqq"
      ]
    },
    {
      "id": "node_005",
      "content": "Other Recommended\nSystemic Therapy, Adenocarcinoma (NSCL-K 1 of 5)\nor Squamous Cell Carcinoma (NSCL-K 2 of 5)",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_009"
      ],
      "tree_ids": [
        "NSCL-K 1 of 5",
        "NSCL-K 2 of 5"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_006",
      "content": "Progression",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [
        "node_008"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_007",
      "content": "Progression",
      "parent_ids": [
        "node_004"
      ],
      "children_ids": [
        "node_008"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_008",
      "content": "Systemic Therapy, Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
      "parent_ids": [
        "node_006",
        "node_007"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-K 1 of 5",
        "NSCL-K 2 of 5"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_009",
      "content": "Progression",
      "parent_ids": [
        "node_005"
      ],
      "children_ids": [
        "node_010"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_010",
      "content": "Dabrafenib + trametinib\nor\nEncorafenib + binimetinib",
      "parent_ids": [
        "node_009"
      ],
      "children_ids": [
        "node_011"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "qqq"
      ]
    },
    {
      "id": "node_011",
      "content": "Progression",
      "parent_ids": [
        "node_010"
      ],
      "children_ids": [
        "node_012"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_012",
      "content": "Systemic Therapy, Subsequent (NSCL-K 4 of 5)",
      "parent_ids": [
        "node_011"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-K 4 of 5"
      ],
      "footnote_labels": []
    },
    {
      "id": "node_013",
      "content": "BRAF V600E mutation discovered during first-line systemic therapy",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_014"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_014",
      "content": "Complete planned systemic therapy, including maintenance therapy, or\nInterrupt current therapy and start Dabrafenib + trametinib (preferred) or Encorafenib + binimetinib (preferred)",
      "parent_ids": [
        "node_013"
      ],
      "children_ids": [
        "node_015"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "qqq"
      ]
    },
    {
      "id": "node_015",
      "content": "Progression",
      "parent_ids": [
        "node_014"
      ],
      "children_ids": [
        "node_016"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_016",
      "content": "Systemic Therapy, Adenocarcinoma (NSCL-K 1 of 5) or Squamous Cell Carcinoma (NSCL-K 2 of 5)",
      "parent_ids": [
        "node_015"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-K 1 of 5",
        "NSCL-K 2 of 5"
      ],
      "footnote_labels": []
    }
  ],
  "tree_references": [
    {
      "from_tree": "NSCL-32",
      "to_tree": "NSCL-K 1 of 5",
      "description": "Systemic Therapy, Adenocarcinoma"
    },
    {
      "from_tree": "NSCL-32",
      "to_tree": "NSCL-K 2 of 5",
      "description": "Systemic Therapy, Squamous Cell Carcinoma"
    },
    {
      "from_tree": "NSCL-32",
      "to_tree": "NSCL-K 4 of 5",
      "description": "Systemic Therapy, Subsequent"
    },
    {
      "from_tree": "NSCL-32",
      "to_tree": "NSCL-H",
      "description": "Principles of Molecular and Biomarker Analysis"
    },
    {
      "from_tree": "NSCL-32",
      "to_tree": "NSCL-J",
      "description": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease"
    }
  ],
  "footnotes": [
    {
      "label": "nn",
      "content": "Principles of Molecular and Biomarker Analysis (NSCL-H)."
    },
    {
      "label": "rr",
      "content": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J)."
    },
    {
      "label": "ss",
      "content": "For PS 0â€“4."
    },
    {
      "label": "qqq",
      "content": "Single-agent vemurafenib or dabrafenib are treatment options if the combination of dabrafenib + trametinib is not tolerated."
    }
  ],
  "extraction_confidence": 0.95,
  "image_title": "BRAF V600E MUTATION",
  "tree_id": "NSCL-32",
  "keywords": [
    "MSI-H",
    "dMMR",
    "TMB"
  ]
}
